139 related articles for article (PubMed ID: 3192050)
41. Prognostic significance of some clinical, morphological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts.
Kerndrup G; Pedersen B; Ellegaard J; Hokland P
Blut; 1986 Jan; 52(1):35-43. PubMed ID: 3455830
[TBL] [Abstract][Full Text] [Related]
42. Decreased expression of the Fas ligand on peripheral blood mononuclear cells and undetectable levels of soluble Fas ligand in the serum of patients with aplastic anemia and myelodysplastic syndrome.
Shinohara K; Takahahi T; Nawata R; Oeda E
Am J Hematol; 1999 Oct; 62(2):124-5. PubMed ID: 10509009
[No Abstract] [Full Text] [Related]
43. Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome.
Molnár L; Berki T; Hussain A; Németh P; Losonczy H
Pathol Oncol Res; 2000; 6(1):18-23. PubMed ID: 10749583
[TBL] [Abstract][Full Text] [Related]
44. Refractory myelodysplastic anaemias with hypocellular bone marrow.
Yoshida Y; Oguma S; Uchino H; Maekawa T
J Clin Pathol; 1988 Jul; 41(7):763-7. PubMed ID: 3410972
[TBL] [Abstract][Full Text] [Related]
45. Pathogenesis and clinical variations in the myelodysplastic syndromes.
Jacobs A; Clark RE
Clin Haematol; 1986 Nov; 15(4):925-51. PubMed ID: 3552349
[No Abstract] [Full Text] [Related]
46. Recombinant human erythropoietin in patients with myelodysplastic syndromes.
Schouten HC; Vellenga E; van Rhenen DJ; de Wolf JT; Coppens PJ; Blijham GH
Leukemia; 1991 May; 5(5):432-6. PubMed ID: 2033964
[TBL] [Abstract][Full Text] [Related]
47. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes.
Rosati S; Anastasi J; Vardiman J
Semin Hematol; 1996 Apr; 33(2):111-26. PubMed ID: 8722682
[No Abstract] [Full Text] [Related]
48. Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome.
Goasguen JE; Bennett JM; Cox C; Hambley H; Mufti G; Flandrin G
Leuk Res; 1991; 15(12):1159-65. PubMed ID: 1766264
[TBL] [Abstract][Full Text] [Related]
49. Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes.
Solé F; Prieto F; Badia L; Woessner S; Florensa L; Caballin MR; Coll MD; Besses C; Sans-Sabrafen J
Cancer Genet Cytogenet; 1992 Nov; 64(1):12-20. PubMed ID: 1458444
[TBL] [Abstract][Full Text] [Related]
50. Refractory anaemia with ring sideroblasts and monosomy 7 in a 10-year-old child.
Delette C; Ferret Y; Claisse JF; Guiheneuf E
Int J Hematol; 2014 Dec; 100(6):521-2. PubMed ID: 25227184
[No Abstract] [Full Text] [Related]
51. Refractory anemia in the elderly.
Gardner FH
Adv Intern Med; 1987; 32():155-75. PubMed ID: 3548248
[TBL] [Abstract][Full Text] [Related]
52. Circulating micromegakaryocytes in myelodysplasia.
Erber WN; Jacobs A; Oscier DG; O'Hea AM; Mason DY
J Clin Pathol; 1987 Nov; 40(11):1349-52. PubMed ID: 3320097
[TBL] [Abstract][Full Text] [Related]
53. [Clinical aspects and diagnosis of refractory anemia with excess of blasts].
Gladysh VV; Turbina NS
Klin Med (Mosk); 1990 Nov; 68(11):84-7. PubMed ID: 2283827
[No Abstract] [Full Text] [Related]
54. Peripheral blood chromosome aberrations in MDS.
White AD; Jacobs A
Cancer Genet Cytogenet; 1992 Apr; 59(2):167-72. PubMed ID: 1581882
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes.
Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P
Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432
[TBL] [Abstract][Full Text] [Related]
56. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.
Ye L; Ren Y; Zhou X; Mei C; Xu W; Ma L; Luo Y; Hu C; Ye X; Wei J; Lou Y; Jin J; Tong H
Blood Cells Mol Dis; 2019 Jul; 77():88-94. PubMed ID: 31005752
[TBL] [Abstract][Full Text] [Related]
57. [Myelodysplastic syndromes or refractory anemias].
Fenaux P
Rev Prat; 1993 Jun; 43(11):1379-85. PubMed ID: 8235387
[TBL] [Abstract][Full Text] [Related]
58. New system for assessing the prognosis of refractory anemia patients.
Matsuda A; Jinnai I; Yagasaki F; Kusumoto S; Murohashi I; Bessho M; Hirashima K; Honda S; Minamihisamatsu M; Fuchigami K; Matsuo T; Kuriyama K; Tomonaga M
Leukemia; 1999 Nov; 13(11):1727-34. PubMed ID: 10557045
[TBL] [Abstract][Full Text] [Related]
59. Refractory cytopenias: clinical course according to bone marrow cytology and cellularity.
Riccardi A; Giordano M; Girino M; Cazzola M; Montecucco CM; Cassano E; Danova M; Ucci G; Castello A; Coci A
Blut; 1987 Mar; 54(3):153-63. PubMed ID: 3814832
[TBL] [Abstract][Full Text] [Related]
60. Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.
Bacher U; Kern W; Alpermann T; Schnittger S; Haferlach C; Haferlach T
Leuk Res; 2012 Jul; 36(7):826-31. PubMed ID: 22554895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
